Presage Biosciences Starts Initial Patient Dosing of Pure Biologics' Antibody Targeting ROR1 for Cancer Therapy
Friday, July 26, 2024
Presage Biosciences, known for its expertise in evaluating oncology drugs within human tumors, has initiated Phase 0 dosing with PBA-0405, an antibody from Pure Biologics that targets ROR1. This antibody is designed to trigger tumor cell destruction through cytotoxic immune cells. The study aims to understand the biological effects of PBA-0405 in the context of the human tumor microenvironment.
Earlier this year, Presage and Pure Biologics received approval from the U.S. Food and Drug Administration to proceed with Phase 0 testing of a pre-GMP first-in-human drug candidate using Presage's Comparative In Vivo Oncology (CIVO®) platform. CIVO allows for microdosing directly into tumors that are planned for surgical removal. This approach provides detailed molecular insights into drug effectiveness by analyzing the expression of thousands of genes within the tumor.
Pure Biologics, expressed enthusiasm about the study, stating, "The dosing of the first patient marks a significant milestone, making PBA-0405 the first ROR1-targeting agent with this unique mechanism to enter clinical trials. We are optimistic about the preclinical data and are eager to evaluate its effects in human studies." ROR1 is a tumor-associated antigen found in various solid tumors and B cell malignancies.
Presage, highlighted the significance of the collaboration, saying, "We are excited to work with Pure Biologics to test their pre-GMP oncology drug in this Phase 0 CIVO study. Our platform accelerates drug development by enabling in situ testing within human tumors. This helps us assess tumor-killing activity, drug interactions, and immuno-oncology effects."
Comparative In Vivo Oncology (CIVO) is Presage's innovative platform for delivering multiple drugs directly into tumors and conducting comprehensive profiling. The CIVO device can simultaneously administer up to eight different drugs or combinations into distinct columns. This technology, paired with advanced techniques like immunohistochemistry, in situ hybridization, and molecular profiling, offers valuable insights into drug activity and supports oncology drug development.
Source: prnewswire.com
